Increasing Demand for Highly-Processed Packaged Food and Beverage Products to Augment Growth of Nisin Market
Nisin is a synthetic polycyclic antibacterial peptides made by the bacterium L. lactis, which is widely used as a pre-packed food preservative. It has 34 unique amino acid residues, with the very rare amino acid methyllanthionine. Nisin has been shown to be effective in inhibiting bacterial growth and preventing pathogenicity of pathogens and organisms, thus making it a promising food preservative.
Nisin inhibits the bacteria's ability to adhere to food particles by forming an adhesive between the food particles and the microorganisms. The sticky substance also prevents the food particles from being washed away during washing or after rinsing, thereby allowing them to penetrate further into the body of the host. When the bacteria are exposed to a suitable concentration of Nisin, it will be unable to attach to the food particles, therefore ensuring that the food remains intact and undisturbed. The use of Nisin as a preservative has long been recommended by health care professionals, as it helps to protect the integrity of foods, as well as prolong the shelf life of the products.
Market Dynamics
Increasing demand for highly-processed packaged food and beverage products is expected to propel growth of the nisin market. For instance, according to the U.S. Department of Agriculture, in 2019, the value of U.S. exports of processed food products to the world reached US$ 6.7 billion, up 7 percent from 2018.
Potential of nisin in the treatment of diabetic foot infections is expected to offer lucrative growth opportunities for players in the nisin market. For instance, the study, ‘Influence of Storage on the Antimicrobial and Cytotoxic Activities of a Nisin-biogel with Potential to be Applied to Diabetic Foot Infections Treatment’, published in November 2020, reported development of a nisin-guar gum biogel to be applied to diabetic foot infections.
Competitive Analysis
Major market players operating in the nisin market include, Amtech Biotech Co., Ltd, Chihon Biotechnology Co., Ltd., Cayman Chemical, ImmuCell Corporation, Danisco A/S, DSM N.V., Galactic, Handary S.A., Royal, Sivelee B.V., Shandong Freda Biotechnology Co., and Zhejiang Silver-Elephant Bio-engineering Co. Ltd.
Major market players operating in the nisin market are focused on R&D to expand their product portfolio. For instance, in February 2019, ImmuCell Corporation made first phased submission to the U.S. Food and Drug Administration (FDA) of the manufacturing technical section (known as the Chemistry, Manufacturing and Controls (CMC) Technical Section) with respect to the Nisin Drug Substance under the Company’s New Animal Drug Application (NADA).

Comments
Post a Comment